Body Protection Compound-157
Evidence Grade C — Moderate human evidence. 201 published studies, 44 human. 2 registered clinical trials.
BPC-157 is a synthetic 15-amino-acid peptide derived from a protein found in human stomach juice. It is one of the most widely discussed research peptides, particularly among people interested in joint, tendon, and gut recovery. It has no approval from any major regulatory agency and has not completed any human Phase III clinical trial. Most of what is known comes from animal studies — predominantly rats — conducted largely by a single research group in Croatia.
201 published studies: 44 human, 99 animal, 20 in-vitro, 40 reviews
BPC-157 has no marketing authorisation from any major regulatory agency. No human Phase III clinical trials have been completed. The preclinical evidence base consists of over 100 animal studies, predominantly conducted at the University of Zagreb. A small pilot study in ulcerative colitis (4 patients) has been reported but was uncontrolled.
No established human dosing, safety profile, or efficacy data from rigorous clinical trials exist. Products available through unregulated channels are not subject to pharmaceutical manufacturing standards, and their composition, purity, and sterility cannot be assured. The gap between the extensive animal literature and the near-complete absence of human clinical data is the defining feature of this compound's evidence base.
Research in animal models suggests BPC-157 may interact with multiple biological pathways including growth factor signalling, nitric oxide systems, and collagen organisation. These proposed mechanisms are derived from preclinical studies, predominantly from a single research group. No mechanisms have been validated in controlled human trials, and the compound's pharmacological activity in humans is not established.
Research in animal models suggests positive effects on tendon healing, gut repair, and nerve regeneration, with results that have been consistently positive across over 100 animal studies. However, the vast majority of this research comes from one group at the University of Zagreb. A small pilot study in ulcerative colitis (4 patients) has been reported but was uncontrolled. The gap between the extensive animal literature and the near-complete absence of human clinical data is the defining feature of BPC-157's evidence base. No established human dosing, safety profile, or pharmacokinetic data exist from rigorous trials. Animal studies have shown no significant toxicity, but this does not guarantee human safety. Products from unregulated sources are not subject to pharmaceutical manufacturing standards, and their composition, purity, and sterility cannot be assured.
BPC 157 for Acute Hamstring Muscle Strain Repair
PCO-02 - Safety and Pharmacokinetics Trial
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
TB-500 has no marketing authorisation from any regulatory agency. No human clinical trials of TB-500 specifically have been conducted. The evidence base relies on animal studies of both TB-500 and its parent molecule thymosin beta-4, which are not pharmacologically equivalent. TB-500 is prohibited by WADA and is known from equine and greyhound racing contexts. Products available through unregulated channels lack pharmaceutical quality assurance. The absence of any human safety or efficacy data means that the compound's effects, risks, interactions, and appropriate dosing in humans are unknown.
ARA-290 (cibinetide) has no marketing authorisation. Phase II trials in sarcoidosis neuropathy showed improvements in corneal nerve fibre density, and a Phase II trial in diabetic neuropathy reported improved metabolic parameters and pain scores. The FDA granted Fast Track designation for sarcoidosis neuropathy. No Phase III trials have been completed. The compound represents an investigational approach to tissue repair that is distinct from existing erythropoietin-based therapies, but its clinical development remains at an early stage.
This entry reflects historical nomenclature for the compound more commonly known as BPC-157. The evidence base, regulatory status, and limitations described for BPC-157 (#81) apply identically to this compound. See compound #81 for the full assessment. No marketing authorisation. No human Phase III trials. No established human dosing or safety profile.
